Astellas is putting the kibosh on a licensing deal with Cartesian Therapeutics, deciding it’s no longer interested in using the latter’s Xork asset to help treat Pompe disease. The decision disclosed ...

Cartesian Growth II ( ($RENEF) ) just unveiled an announcement. On December 29, 2025, Cartesian Growth Corporation II issued a $200,000 unsecured, ...

Cartesian Growth Corp. III Class A ( ($CGCT) ) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial ...

Factorial Inc. (“Factorial”), a leader in solid-state battery technology, and Cartesian Growth Corporation III (“Cartesian III”), a special purpose acquisition company, announced today that they have ...

Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...

The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D.

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...